Lycia Therapeutics

Executive Summary

Lycia Therapeutics is a private biotechnology company pioneering targeted protein degradation via the lysosomal pathway. Leveraging its proprietary LYTAC (Lysosome-Targeting Chimaera) platform, the company aims to degrade extracellular and membrane-bound proteins implicated in various diseases, including cancer and autoimmune disorders. With $106.6 million raised to date, Lycia has advanced its lead programs toward clinical development, focusing on validated targets where existing modalities have limited success. The company's technology has garnered significant investor interest, though clinical validation remains pending. Lycia's near-term prospects hinge on successful IND filings and initial clinical data, which could unlock substantial value in the competitive protein degradation space.

Upcoming Catalysts (preview)

• TBDIND filing for lead program in oncology70% success
• TBDInitial preclinical proof-of-concept data in autoimmune indications60% success
• TBDPotential strategic partnership or series C financing50% success